Paul Hastings Acquires Shares of enGene Therapeutics
Paul Hastings bought 31,000 shares of enGene Therapeutics, signaling insider confidence.
Key Points
- Paul Hastings purchased 31,000 shares of enGene Therapeutics Inc. (ENGN) on June 16, 2026.
- enGene Therapeutics has a market cap of approximately $117.2 million and trades near $1.75.
- The company, focused on bladder cancer treatments, operates in the biotechnology sector and is based in Montreal.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Paul Hastings, a notable figure in the biotechnology sector, recently bought 31,000 shares of enGene Therapeutics Inc. (NasdaqCM:ENGN) on June 16, 2026. This transaction was not part of a pre-planned trading program, suggesting a personal vote of confidence in the company’s prospects.
enGene Therapeutics Inc. Stock Down 4.7%
Shares of enGene Therapeutics Inc. are currently trading around $1.75. The company, which operates in the biotechnology sector, has a market capitalization of about $117.2 million. It has a 52-week trading range between $1.40 and $12.25, indicating some volatility. The firm's 50-day moving average is $4.33, while the 200-day moving average stands at $7.13. enGene Therapeutics maintains a strong liquidity position with a current ratio of 12.57 and a quick ratio of 12.07, though it has a debt-to-equity ratio of 13.07.
About enGene Therapeutics
enGene Therapeutics Inc., based in Montreal, Canada, is a clinical-stage biotechnology company focused on developing genetic medicines. The company’s main product candidate, detalimogene voraplasmid, is a monotherapy aimed at treating non-muscle invasive bladder cancer (NMIBC). enGene also has other projects in its pipeline, including the LEGEND program, which is currently in Phase 2 trials. Under the leadership of CEO Ronald H. W. Cooper, the company employs 81 people.
Bottom Line
Paul Hastings' acquisition of enGene Therapeutics shares is a noteworthy insider move that might reflect confidence in the company’s future. While 13F filings and insider transactions provide valuable insights into investor sentiment, they are backward-looking and may not represent the current position. Investors often track these activities to gauge insider perspectives on company performance and potential growth.
Get enGene Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $ENGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.